---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-260859"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2021-08-30T23:59:59+00:00"
generated_at: "2026-06-29T06:57:04.528167+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ziopharm appoints Kevin S. Boyle as CEO effective Aug 30, 2021; Heidi Hagen returns to Board

## Summary
- Kevin S. Boyle named CEO and director; base salary $600K, target bonus 60%, sign-on bonus $50K.
- Equity awards: option for 2,625,000 shares and 875,000 RSUs, each vesting over 4 years.
- Heidi Hagen steps down as interim CEO, remains on Board (since June 2019).
- Raffaele Baffa appointed Head of R&D in addition to CMO; Adam Levy named EVP Corp Dev & IR.
- Boyle most recently CEO of Kuur Therapeutics, led $185M acquisition by Athenex in May 2021.

## SEC filing metadata
- accession: 0001193125-21-260859
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2021-08-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/0001193125-21-260859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/d11000d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-260859
- JSON: https://secwatch.observer/filing/0001193125-21-260859.json
- Plain text: https://secwatch.observer/filing/0001193125-21-260859.txt

## Key facts
- Executive change
  Kevin S. Boyle, Sr. was appointed as Chief Executive Officer and Director at Alaunos Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and Director
  source text: On August 22, 2021, the board of directors, or the Board, of ZIOPHARM Oncology, Inc., or the Company, appointed Kevin S. Boyle, Sr., age 48, as Chief Executive Officer of the Company, effective August 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/0001193125-21-260859-index.htm
- Executive change
  Heidi Hagen resigned as Interim Chief Executive Officer at Alaunos Therapeutics, Inc..
  - Action: resigned
  - Role: Interim Chief Executive Officer
  source text: Heidi Hagen, who has served as the Company’s Interim Chief Executive Officer since February 2021, will resign as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/0001193125-21-260859-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.